Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Maze Therapeutics, Inc.NASDAQ: MAZE
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin at 97.8%
Gross margin was 97.8% in Q1 FY2026. On a trailing-twelve-month basis it was 92.0%, down 8.0 pp year over year.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2024
- 100.0%
- Year-over-year change
- —
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | 100.0% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
Gross Margin vs competitors
How MAZE compares with its peers on the latest reported figures
- MAZE's LTM Mar 2026 gross margin of 92.0% is the 2nd highest of the 7 companies compared; the peer median is 81.0%.
- Its year-over-year change of -8.0 pp is the 3rd highest of 7, against a peer median of -17.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BIOABioAge Labs, Inc. | LTM Mar 2026 | 99.4% | -0.6 pp | — |
| LTM Mar 2026 | 92.0% | -8.0 pp | — | |
| LTM Mar 2026 | 91.9% | +7.7 pp | -2.6 pp | |
| LTM Jun 2026 | 82.1% | -14.9 pp | +2.2 pp | |
SEPNSepterna, Inc. | LTM Sep 2026 | 79.9% | -20.1 pp | — |
| LTM Sep 2026 | 60.7% | -37.0 pp | +1.9 pp | |
| FY2025 | 33.7% | -66.3 pp | -106.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding MAZE) | 81.0% | -17.5 pp | -0.3 pp | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.